

# Angela Buonadonna

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3319799/angela-buonadonna-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125  
papers

5,519  
citations

35  
h-index

73  
g-index

167  
ext. papers

6,661  
ext. citations

4  
avg, IF

4.86  
L-index

#	Paper	IF	Citations
125	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1609-18	59.2	663
124	Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 1238-47	2.2	540
123	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv51-iv67	10.3	316
122	The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 3061-8	2.2	280
121	Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 337-44	2.2	253
120	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv79-iv95	10.3	223
119	Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2018</b> , 29, iv68-iv78	10.3	207
118	Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2457-65	2.2	183
117	Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. <i>European Journal of Cancer</i> , <b>1998</b> , 34, 632-40	7.5	180
116	Ifosfamide in the adjuvant therapy of soft tissue sarcomas. <i>Oncology</i> , <b>2003</b> , 65 Suppl 2, 80-4	3.6	146
115	Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 866-71	2.2	128
114	Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1054-65	9.7	126
113	Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. <i>Journal of Clinical Oncology</i> , <b>1997</b> , 15, 1385-94	2.2	101
112	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 497-507	21.7	98
111	Prognostic factors in soft tissue sarcomas: a study of 395 patients. <i>European Journal of Surgical Oncology</i> , <b>2002</b> , 28, 153-64	3.6	93
110	Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. <i>Journal of Clinical Oncology</i> , <b>1996</b> , 14, 1885-94	2.2	89
109	Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 1217-25	3.9	83

108	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. <i>Annals of Oncology</i> , <b>2015</b> , 26, 542-7	10.3	76
107	Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1749-59	10.3	73
106	Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3686-93	3.1	70
105	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1373-1378	10.3	61
104	Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. <i>Annals of Oncology</i> , <b>2003</b> , 14, 1135-41	10.3	61
103	Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. <i>Annals of Oncology</i> , <b>2018</b> , 29, 924-930	10.3	60
102	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 784-92	7.5	59
101	Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1528-1534	10.3	58
100	Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1059-64	10.3	51
99	Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2971-80	7.5	48
98	Solid pseudopapillary tumour of the pancreas. <i>Lancet Oncology, The</i> , <b>2003</b> , 4, 255-6	21.7	41
97	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. <i>Pharmacogenetics and Genomics</i> , <b>2013</b> , 23, 549-57	1.9	38
96	Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. <i>Annals of Oncology</i> , <b>1999</b> , 10, 539-45	10.3	37
95	Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients. <i>Thrombosis Research</i> , <b>1995</b> , 78, 127-37	8.2	37
94	FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , <b>2016</b> , 27, 843-9	10.3	36
93	Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. <i>Lung Cancer</i> , <b>2011</b> , 72, 340-7	5.9	36
92	Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6901-7	12.9	32
91	Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. <i>PLoS ONE</i> , <b>2014</b> , 9, e84940	3.7	28

90	Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 918-924	12.9	27
89	The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 134, 110-118	5.3	26
88	Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 123-130	6.1	23
87	Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy. <i>Annals of Oncology</i> , <b>2003</b> , 14, 843-8	10.3	23
86	Epirubicin and ifosfamide in advanced soft tissue sarcomas. <i>Annals of Oncology</i> , <b>1993</b> , 4, 669-72	10.3	22
85	HLA-G 3RTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. <i>PLoS ONE</i> , <b>2015</b> , 10, e0144000	3.7	22
84	A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma. <i>Anti-Cancer Drugs</i> , <b>2017</b> , 28, 1157-1165	2.4	21
83	Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review). <i>Molecular Medicine Reports</i> , <b>2011</b> , 4, 203-8	2.9	20
82	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCR): Results of the phase III randomized TRIBE trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 336-336	2.2	20
81	and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 7859-7866	3.3	18
80	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 6674-6684	5.6	18
79	Malignant cardiac tumors: diagnosis and treatment. <i>Future Cardiology</i> , <b>2015</b> , 11, 485-500	1.3	17
78	Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. <i>Annals of Oncology</i> , <b>2005</b> , 16, 716-25	10.3	17
77	The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 994-1002	6.1	17
76	Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STs) Protocol 0303. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 3872-3879	3.1	16
75	Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 2425-2434	3.9	16
74	Probe-based confocal laser endomicroscopy for in vivo evaluation of the tumor vasculature in gastric and rectal carcinomas. <i>Scientific Reports</i> , <b>2017</b> , 7, 9819	4.9	15
73	Malignant pericardial effusion: sclerotherapy or local chemotherapy?. <i>British Journal of Cancer</i> , <b>2009</b> , 101, 734-5; author reply 736-7	8.7	15

72	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , <b>2019</b> , 24, 385-393	5.7	15
71	UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. <i>Liver International</i> , <b>2017</b> , 37, 1345-1353	7.9	14
70	The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 878-886	8.7	12
69	Association of -3 rs1053004 and rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 367	5.6	11
68	Characterizing Metastatic -Positive Gastric Cancer at the Haplotype. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 19,	6.3	11
67	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. <i>Oncotarget</i> , <b>2016</b> , 7, 19784-19793	7.3	11
66	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	10
65	HLA-G 3RTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	9
64	Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 4302-4309	3.1	9
63	Exocrine and endocrine modulation in common gastric carcinoma. <i>American Journal of Clinical Pathology</i> , <b>2012</b> , 137, 712-21	1.9	9
62	Development and validation of LC-MS/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225225	3.7	9
61	Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer. <i>Cancers</i> , <b>2019</b> , 11,	6.6	8
60	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 565-571	8.7	8
59	Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 712	5.6	8
58	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. <i>Annals of Oncology</i> , <b>2007</b> , 18, 1177-84	10.3	8
57	Neoadjuvant Therapy of Rectal Cancer New Treatment Perspectives. <i>Tumori</i> , <b>2004</b> , 90, 373-378	1.7	8
56	Continuous Infusion Fluorouracil in the Management of Advanced Breast Cancer: A Phase II Study. <i>Tumori</i> , <b>2000</b> , 86, 42-45	1.7	8
55	Increasing dose of Continuous Infusion Ifosfamide and Fixed dose of Bolus Epirubicin in Soft Tissue Sarcomas. A Study of the Italian Group on Rare Tumors. <i>Tumori</i> , <b>1999</b> , 85, 229-233	1.7	8

54	Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. <i>Scientific Reports</i> , <b>2019</b> , 9, 13008	4.9	7
53	Gastric Cancer with Bone Marrow Invasion at Presentation: Case-Report and Review of the Literature. <i>Tumori</i> , <b>1995</b> , 81, 74-76	1.7	7
52	FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO).. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3543-3543	2.2	7
51	Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
50	Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma. <i>Sarcoma</i> , <b>2016</b> , 2016, 6862090	3.1	7
49	A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach. <i>Cancer Biology and Therapy</i> , <b>2018</b> , 19, 254-259	4.6	7
48	Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 475	5.7	6
47	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2020</b> , 25, 661-668	5.7	6
46	Morphologic shift associated with aberrant cytokeratin expression in a GIST patient after tyrosine kinase inhibitors therapy. A case report with a brief review of the literature. <i>Pathology Research and Practice</i> , <b>2016</b> , 212, 63-7	3.4	6
45	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STIS 1001 randomized trial. <i>Cancer</i> , <b>2021</b> , 128, 85	6.4	6
44	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1312	5.3	6
43	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFR Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 36	5.6	5
42	Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients. <i>International Journal of Clinical Oncology</i> , <b>2013</b> , 18, 510-6	4.2	5
41	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 657-657	2.2	5
40	Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 183-190	8.7	5
39	Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group. <i>Cancers</i> , <b>2021</b> , 13,	6.6	5
38	Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma. <i>Journal of Mass Spectrometry</i> , <b>2017</b> , 52, 283-289	2.2	4
37	Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 149, 30-37	5.3	4



36	Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems. <i>Oncologist</i> , <b>2020</b> , 25, e1254	4	4
35	Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST. <i>International Journal of Colorectal Disease</i> , <b>2014</b> , 29, 639-40	3	4
34	Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer. <i>Neoplasia</i> , <b>2014</b> , 16, 751-6	6.4	4
33	Long-Term Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Continuous Intravenous Infusion of Recombinant Interleukin-2: The Experience of a Single Institution. <i>Tumori</i> , <b>2003</b> , 89, 400-404	1.7	4
32	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1101	5.6	4
31	Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 1017-1021	4.6	3
30	FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1606-7	10.3	3
29	Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , <b>2020</b> , 139, 81-89	7.5	3
28	A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity. <i>Journal of Personalized Medicine</i> , <b>2020</b> , 10,	3.6	3
27	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 1179-1187	2.6	2
26	DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3532-3532	2.2	2
25	CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 839-845	8.7	2
24	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
23	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835919899850	5.4	1
22	Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 1439-43	4.6	1
21	Neoadjuvant epirubicin, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4066-4066	2.2	1
20	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , <b>2020</b> , 16, 2645-2660	3.6	1
19	Feasibility and Oncological Outcome of Preoperative Chemoradiation With IMRT Dose Intensification for Locally Advanced Esophageal and Gastroesophageal Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 626275	5.3	1

18	Ventricular Arrhythmias Due to Glomangiosarcoma Cardiac Metastases. <i>JACC: CardioOncology</i> , <b>2021</b> , 3, 150-153	3.8	o
17	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , <b>2022</b> , 170, 64-72	7.5	o
16	Diagnostic, Prognostic, Predictive and Therapeutic Tissue Biomarkers in Gastric Cancer. <i>Current Clinical Pathology</i> , <b>2019</b> , 83-106	0.1	
15	New Agents in the Treatment of Advanced Gastric Cancer: Targeted Therapy and Immunotherapy. <i>Current Clinical Pathology</i> , <b>2019</b> , 121-132	0.1	
14	Combined Modality Treatment for Locally Advanced Gastric Cancer: Current Evidences and New Perspectives. <i>Current Clinical Pathology</i> , <b>2019</b> , 133-145	0.1	
13	Surgical Strategies in Gastric Cancer. <i>Current Clinical Pathology</i> , <b>2019</b> , 147-152	0.1	
12	Probe-based confocal laser endomicroscopy (pCLE) is a suitable method for extrapulmonary high grade neuroendocrine rectal carcinoma (HGNEC) evaluation. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 4577-4583	4.4	
11	High-Dose Epirubicin in Locally Advanced Operable Noninflammatory Breast Cancer: A Feasibility Trial. <i>Tumori</i> , <b>1997</b> , 83, 656-660	1.7	
10	Efficacy of Total Androgen Blockade in Metastatic Prostatic Carcinoma with Transient Hypogonadotropic Hypogonadism: A Case Report. <i>Tumori</i> , <b>1999</b> , 85, 280-283	1.7	
9	Anthracycline dose and liver dysfunction. <i>British Journal of Cancer</i> , <b>1999</b> , 79, 1943	8.7	
8	Neoadjuvant chemotherapy (CT) and postoperative chemoradiation (PCRT) in locally advanced, resectable, gastric cancer (LAGC). Preliminary results of a pilot study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 15078-15078	2.2	
7	An observational, multicenter, retrospective, Italian Sarcoma Group (ISG) study of trabectedin in patients with advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e23502-e23502 <sup>2.2</sup>	2.2	
6	Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3534-3534	2.2	
5	Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3536-3536	2.2	
4	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 11045-11045	2.2	
3	Evidence-Based Medicine: What does it Mean and Where Are We Going? <b>2010</b> , 221-241		
2	A UGT1A1 genotype-guided dosing study of irinotecan in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus bevacizumab (BEV).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 562-562 <sup>2.2</sup>	2.2	
1	Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , <b>2019</b> , 23, 46-49	1.3	



